DKSH Partnered with R-Biomeds to Bring Oncology, Bio-similars, and Thyroid Treatments to Cambodia

Cambodia, Phnom Penh, October 8, 2024 - DKSH Business Unit Healthcare, a leading partner for healthcare companies seeking to grow their business in Asia and beyond, has signed an exclusive agreement with R-Biomeds, a global pharmaceutical company based in Singapore. As part of this exclusive partnership, DKSH will expand R-Biomeds‘s range of pharmaceuticals, including Oncology, Bio-similars, and Thyroid medicines, to the Cambodian market.

As a strategic partner, DKSH has been collaborating with R-Biomeds to drive growth in Myanmar and, with great success, is now expanding the partnership in Cambodia. DKSH Cambodia will help R-Biomeds grow its business, solidify its brand presence, and gain market share by managing R-Biomeds's distribution and logistics, marketing, and sales. Its experienced teams and broad distribution network will ensure that its products reach modern and traditional trade, hospitals, clinics, other medical channels, and patients in need nationwide.

Rajeev Rawal, Managing Director of R-Biomeds, commented: “We are delighted to partner with DKSH to bring our high-quality medicines to patients in Cambodia. We are confident in DKSH's strong nation-wide footprint, extensive distribution network, and expertise to further strengthen R-Biomeds's brands and growth in this market.”

Philip Wray, Vice President of Healthcare at DKSH in Cambodia, said: “With our expertise in Market Expansion Services, we are proud to be R-Biomeds’s trusted and strategic partner. Our partnership demonstrates our commitment to providing patients with better health and quality of life, in line with DKSH's purpose to enrich people's lives and our mission of healthcare for all.”.